Structure via PubChem · Public domain (PubChem)
(RS)-adrafinil
Sign in to saveAdrafinil, sold under the brand name Olmifon, is a wakefulness-promoting medication that was formerly used in France to improve alertness, attention, wakefulness, and mood, particularly in the elderly. It was also used off-label by individuals who wished to avoid fatigue, such as night workers or others who needed to stay awake and alert for long periods of time. Additionally, the medication has been used non-medically as a novel vigilance-promoting agent.
Key facts
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 477243010
- Drug.IUPAC_name
- (±)-2-Benzhydrylsulfinylethanehydroxamic acid
- Drug.image
- Adrafinil.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 200
- Drug.image2
- Adrafinil.png
- Drug.image_class2
- bg-transparent
- Drug.tradename
- Olmifon
- Drug.legal_AU
- S4
- Drug.legal_US
- Unapproved drug; use in dietary supplements, food, or medicine is unlawful.
- Drug.routes_of_administration
- Oral
- Drug.bioavailability
- 80%
- Drug.metabolism
- 75% (liver)
- Drug.metabolites
- Modafinil
- Drug.elimination_half life
- 1 hour (T1/2 is 12–15 hours for modafinil)
- Drug.excretion
- Kidney
via Wikipedia infobox
Chemical data
- Formula
- C15H15NO3S
- Molecular weight
- 289.4 g/mol
- IUPAC name
- 2-benzhydrylsulfinyl-N-hydroxyacetamide
- SMILES
- C1=CC=C(C=C1)C(C2=CC=CC=C2)S(=O)CC(=O)NO
- InChIKey
- CGNMLOKEMNBUAI-UHFFFAOYSA-N
- XLogP
- 1.6
- Polar surface area
- 85.6 Ų
- H-bond donors
- 2
- H-bond acceptors
- 4
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 2
- Molecule type
- Small molecule
- Indications
- attention deficit hyperactivity disorder
via ChEMBL · EBI
Research
1 papers- LC-ESI-MS determination and pharmacokinetics of adrafinil in rats.Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2008
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 289.077
- Has use
- medication
Show 5 more facts
- chemical formula
- C₁₅H₁₅NO₃S
- World Health Organisation international non-proprietary name
- adrafinil
- canonical SMILES
- C1=CC=C(C=C1)C(C2=CC=CC=C2)S(=O)CC(=O)NO
- Commons category
- Adrafinil
- subject has role
- nootropic
Sources (2)
via Wikidata · CC0
~7 min read
Encyclopedic overview
19 sectionsContents
- Medical uses
- Available forms
- Side effects
- Pharmacology
- Pharmacodynamics
- Pharmacokinetics
- Chemistry
- Synthesis
- History
- Society and culture
- Names
- Regulation
- Athletic doping
- Additive in United States dietary supplements
- New Zealand
- Research
- References
- Further reading
- External links
Adrafinil, sold under the brand name Olmifon, is a wakefulness-promoting medication that was formerly used in France to improve alertness, attention, wakefulness, and mood, particularly in the elderly. It was also used off-label by individuals who wished to avoid fatigue, such as night workers or others who needed to stay awake and alert for long periods of time. Additionally, the medication has been used non-medically as a novel vigilance-promoting agent.
Adrafinil is a prodrug; it is primarily metabolized in vivo to modafinil, resulting in very similar pharmacological effects. Unlike modafinil, however, it takes time for the metabolite to accumulate to active levels in the bloodstream. Effects usually are apparent within 45–60 minutes when taken orally on an empty stomach.
Excerpted from Wikipedia’s “(RS)-adrafinil” article, available under the CC BY-SA 4.0 licence.